ANAHEIM, Calif., Feb. 16, 2012 /PRNewswire/ -- Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR) today announced the appointment of Scott M. Whitcup, M.D., 52, to its Board of Directors. Dr. Whitcup is currently Executive Vice President, Research & Development and Chief Scientific Officer at Allergan, Inc. In that position, he is responsible for leading Allergan's global research and development organization, including medical affairs, drug discovery and medical device research, as well as the global development programs that include ophthalmology, BOTOX®/neurology, medical dermatology, medical aesthetics, plastic surgery, urology and the surgical treatment of obesity.
"Dr. Whitcup is a highly-regarded leader in the biopharmaceutical industry with extensive experience in multiple therapeutic areas including autoimmune diseases, ophthalmology, CNS disease and dermatology," said Virgil D. Thompson, Chairman of the Board of Questcor Pharmaceuticals. "The growth strategies and product manufacturing for Acthar (H.P. Acthar Gel®) and Botox® have some interesting parallels. We believe that Scott's pivotal role in the growth of Botox® as a treatment for a range of medical conditions will benefit Questcor as we increase our scientific efforts to explore the potential for Acthar to treat additional autoimmune conditions."
"I am pleased to add my expertise into the mix of talent already on the board and management team of Questcor and look forward to assisting the Company in executing its strategic plans," noted Dr. Whitcup.
Dr. Whitcup joined Allergan in 2000, has been Executive Vice President, Research and Development since July 2004 and in April 2009 became Chief Scientific Officer. While at Allergan, he has been instrumental in obtaining approximately 20 major regulatory approvals including Botox® for chronic migrai
|SOURCE Questcor Pharmaceuticals, Inc.|
Copyright©2010 PR Newswire.
All rights reserved